APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.5% | 97.4% | 97.2% | 97.5% | 95.1% | 92.5% | 89.1% | 90.1% | 92.0% | 93.6% | 94.4% | 95.0% | |
| 67.3% | 55.3% | 44.5% | 39.3% | 39.8% | 44.0% | 46.5% | 44.4% | 45.2% | 45.3% | 43.5% | 37.6% | |
| 68.3% | 56.9% | 44.7% | 39.3% | 40.7% | 44.0% | 47.0% | 44.4% | 45.2% | 45.3% | 43.5% | 37.6% | |
| 14.0% | 22.9% | 26.2% | 32.2% | 34.1% | 31.5% | 30.7% | 30.3% | 27.9% | 33.5% | 34.1% | 41.1% | |
| 11.7% | 14.1% | 18.6% | 19.4% | 17.9% | 13.4% | 9.3% | 10.2% | 14.7% | 11.6% | 13.3% | 12.1% | |
| 62.3% | 71.6% | 75.3% | 67.9% | 70.8% | 73.7% | 74.2% | 79.7% | 81.0% | 62.1% | 65.6% | 61.7% | |
| 19.1% | 22.7% | 31.4% | 25.9% | 18.7% | 21.2% | 21.0% | 22.1% | 24.4% | 26.4% | 30.1% | 26.2% | |
| 0.6% | 0.7% | 0.8% | 10.8% | 0.7% | 0.8% | 0.8% | 0.9% | 0.9% | 9.5% | 9.4% | 9.3% | |
| 3.0% | 2.2% | 4.8% | 3.2% | 4.2% | 4.7% | 4.4% | 6.8% | 6.6% | 3.6% | 5.3% | 4.5% | |
| 10.1% | 11.4% | 11.8% | 11.2% | 50.5% | 50.1% | 51.2% | 56.2% | 55.3% | 34.1% | 33.6% | 33.5% | |
| 37.7% | 28.4% | 24.7% | 32.1% | 29.2% | 26.3% | 25.8% | 20.3% | 19.0% | 37.9% | 34.4% | 38.3% | |
| -284.9% | -336.0% | -359.8% | -349.1% | -325.2% | -332.5% | -343.0% | -387.4% | -385.9% | -279.0% | -280.2% | -276.6% | |
| 13.0% | 14.7% | 15.4% | 14.8% | 13.7% | 13.7% | 14.0% | 15.5% | 15.3% | 11.9% | 11.7% | 11.6% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.